



Texas Medicaid

Top 50 Therapeutic Classes by Expenditures

SFY 2010 - Year to Date Fourth Quarter (9/01/2009 - 8/31/2010)

Rank	Therapeutic Class	PDL Class	Number of Drugs in Class	Number of Claims per Class	Amount Paid per Class
1	ANTIPSYCHOTICS Total	Y	29	793,558	\$ 297,587,952
2	STIMULANTS AND RELATED AGENTS Total	Y	26	939,929	\$ 150,778,078
3	ANTICONSULTANTS Total	N	65	1,042,731	\$ 109,521,209
4	GLUCOCORTICOIDS, INHALED Total	Y	14	529,370	\$ 107,124,546
5	CEPHALOSPORINS AND RELATED ANTIBIOTICS Total	Y	21	1,305,872	\$ 93,728,102
6	PROTON PUMP INHIBITORS Total	Y	14	481,139	\$ 91,018,294
7	LEUKOTRIENE MODIFIERS Total	Y	3	636,219	\$ 84,718,528
8	BRONCHODILATORS, BETA AGONIST Total	Y	17	1,231,854	\$ 68,980,815
9	COUGH AND COLD, NON-NARCOTIC Total	Y	194	2,294,414	\$ 56,851,851
10	INTRANASAL RHINITIS AGENTS Total	Y	15	566,648	\$ 47,140,844
11	HYPOGLYCEMICS, INSULIN AND RELATED AGENTS Total	Y	20	228,667	\$ 46,841,791
12	ANTIVIRAL MONOCLONAL ANTIBODIE Total	N	1	27,584	\$ 46,187,032
13	ANTIHEMOPHILIC FACTORS Total	N	17	1,582	\$ 37,428,511
14	ANTIDEPRESSANTS, OTHER Total	Y	26	387,603	\$ 37,026,960
15	GROWTH HORMONE Total	Y	10	11,347	\$ 35,380,415
16	LIPOTROPICS, STATINS Total	Y	14	283,482	\$ 26,998,411
17	ANALGESICS, NARCOTICS SHORT Total	Y	83	1,334,067	\$ 24,513,431
18	NSAIDS Total	Y	44	1,709,006	\$ 23,559,915
19	ANTIDEPRESSANTS, SSRIs Total	Y	16	469,489	\$ 21,256,725
20	ACNE AGENTS, TOPICAL Total	Y	54	153,681	\$ 20,753,179
21	CYTOKINE AND CAM ANTAGONISTS Total	Y	10	9,992	\$ 20,741,865
22	ANTIVIRALS, ORAL Total	Y	13	196,080	\$ 20,385,594
23	MACROLIDES/KETOLIDES Total	Y	20	886,174	\$ 20,077,215
24	PRENATAL VITAMIN PREPARATIONS Total	N	156	288,658	\$ 17,968,654
25	ANALGESICS, NARCOTICS LONG Total	Y	13	46,616	\$ 17,675,021
26	ANGIOTENSIN MODULATORS Total	Y	49	383,168	\$ 17,251,892
27	PENICILLINS Total	N	21	1,335,048	\$ 15,728,031
28	ANTIVIRALS, HIV-SPECIFIC, PROT Total	N	7	26,265	\$ 15,290,204
29	OPHTHALMIC ANTIBIOTICS Total	Y	25	323,880	\$ 14,956,524
30	CONTRACEPTIVES,ORAL Total	N	83	234,384	\$ 14,788,114
31	OTIC ANTIBIOTICS Total	Y	8	164,129	\$ 14,560,641
32	PLATELET AGGREGATION INHIBITORS Total	Y	6	66,193	\$ 14,408,639

Rank	Therapeutic Class	PDL Class	Number of Drugs in Class	Number of Claims per Class	Amount Paid per Class
33	ANTIFUNGALS, TOPICAL Total	Y	38	433,339	\$ 14,165,360
34	ANTIHISTAMINES, MINIMALLY SEDATING Total	Y	27	904,426	\$ 13,243,470
35	HYPOGLYCEMICS, TZD Total	Y	6	45,168	\$ 13,242,421
36	MUCOLYTICS Total	N	2	7,926	\$ 12,285,360
37	COUGH AND COLD, COLD Total	Y	235	526,244	\$ 11,999,441
38	GLUCOCORTICOIDS Total	N	33	614,437	\$ 11,592,609
39	IMMUNOSUPPRESSIVES Total	N	14	25,477	\$ 11,484,135
40	ANTI-ANXIETY DRUGS Total	N	18	743,520	\$ 11,401,050
41	AMINOGLYCOSIDES Total	N	7	5,318	\$ 11,096,271
42	AGENTS TO TREAT MULTIPLE SCLER Total	N	6	3,865	\$ 10,957,341
43	LIPOTROPICS, OTHER Total	Y	26	84,567	\$ 10,375,911
44	ANTIVIRALS, HIV-SPEC, NUCLEOSI Total	N	1	11,455	\$ 10,309,249
45	ANTICOAGULANTS, INJECTABLE Total	Y	3	12,335	\$ 10,304,160
46	BRONCHODILATORS, ANTICHOLINERGIC Total	Y	6	87,339	\$ 10,214,473
47	OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS Total	Y	15	105,224	\$ 10,055,126
48	ARTV CMB NUCLEOSIDE,NUCLEOTIDE Total	N	1	6,782	\$ 10,003,759
49	ANTIPARASITICS, TOPICAL Total	Y	8	146,514	\$ 9,602,414
50	HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS Total	Y	9	32,818	\$ 9,467,136

Total YTD Quarter 4 - Top 50 Therapeutic Classes by Amount Paid per Class	22,185,583	\$1,833,028,663
--	-------------------	------------------------

Total YTD Quarter 4 - All Drugs	31,734,023	\$2,261,060,055
--	-------------------	------------------------

Drug Rebate Revenue¹

Total YTD Quarter 4 Rebate Revenue - Top 50 Therapeutic Classes	Federal Rebates	\$ 687,247,408
	Supplemental Rebates	\$ 119,857,468

Total YTD Quarter 4 Rebate Revenue - All Drugs	Federal Rebates	\$ 814,871,058
	Supplemental Rebates	\$ 127,660,133

¹ Note: Rebate revenues collected in this quarter are for claims paid in the period ending two quarters prior. All amounts are All Funds Amounts Paid and Rebate revenues do not include physician-administered drugs (J-Codes).

Source: Magellan Medicaid Administration, Inc. (as of 10/20/2010)